Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 4601  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission

Year : 2021  |  Volume : 13  |  Issue : 2  |  Page : 163-171

A narrative review of antiviral drugs used for COVID-19 pharmacotherapy

1 Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Deoghar, Jharkhand, India
2 Department of Pharmacology, Kanti Devi Medical College Hospital and Research Center (KDMCH&RC), Mathura, Uttar Pradesh, India

Correspondence Address:
Dr. Manoj K Saurabh
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Deoghar 814152, Jharkhand
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jpbs.JPBS_498_20

Rights and Permissions

Purpose: A number of research articles has been published evaluating safety and efficacy of drugs against COVID-19. This study was undertaken to collate and review the information regarding common proposed anti- viral drugs for easy reference. Methods: The literature was search was done using terms like severe acute respiratory syndrome or SARS-CoV-2 or 2019-nCoV or SARS-CoV or COVID-19 in combination with drugs or treatment or pharmaco-therapy using PubMed and google scholar to identify relevant articles. Results: Despite showing good early results, hydroxychloroquine and lopinavir-ritonavir has not shown clinical benefit in randomized controlled trials. However lopinavir in combination with other drugs specially interferon is being investigated. Remdesivir has shown positive effect in terms of clinical improvement and continued to being investigated alone or in combination with other drugs. Favipiravir has shown mixed results and more data from adequately powered study is needed to prove its efficacy. Conclusions: Many drugs which showed positive effect in initial studies could not replicate the same benefit in large randomized controlled trials. There is need to evaluate efficacy and safety of drugs based on high quality evidence before allowing it to be used in general population.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded77    
    Comments [Add]    

Recommend this journal